Company profile for PolarityTE

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At PolarityTE, we’re aiming to be the first company to truly deliver regenerative medicine into clinical practice, fulfilling the long unmet promise that tissue engineering has failed to achieve. We utilize a patient’s own cells and tissues to regenerate functionally-polarized human tissue. PolarityTE is built on the principle that self must regenerate self. We are revolutionizing regenerative medicine and inducing a pa...
At PolarityTE, we’re aiming to be the first company to truly deliver regenerative medicine into clinical practice, fulfilling the long unmet promise that tissue engineering has failed to achieve. We utilize a patient’s own cells and tissues to regenerate functionally-polarized human tissue. PolarityTE is built on the principle that self must regenerate self. We are revolutionizing regenerative medicine and inducing a paradigm shift through our innovative platform technology, incredible team, expanding network and drive to be different.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1960 South 4250 West Salt Lake City, UT 84104
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/05/20/2884798/0/en/PolarityTE-Secures-22-5-Million-Financing-to-Advance-SkinTE-Phase-III-Pivotal-Study-in-Diabetic-Foot-Ulcers.html

GLOBENEWSWIRE
20 May 2024

https://www.globenewswire.com//news-release/2024/02/26/2835136/0/en/PolarityTE-Announces-First-Subject-Screened-in-Phase-III-Pivotal-Study-Evaluating-Investigational-New-Drug-SkinTE-in-Diabetic-Foot-Ulcers.html

GLOBENEWSWIRE
26 Feb 2024

https://www.biospace.com/article/releases/polarityte-confirms-receipt-of-unsolicited-non-binding-offer-to-acquire-the-company/?s=79

BIOSPACE
09 Nov 2022

https://www.prnewswire.com/news-releases/polarityte-reports-second-quarter-2022-financial-results-and-provides-business-update-301604447.html

PRNEWSWIRE
11 Aug 2022

https://www.prnewswire.com/news-releases/polarityte-reports-first-quarter-2022-financial-results-and-provides-business-update-301547407.html

PRNEWSWIRE
16 May 2022

https://www.prnewswire.com/news-releases/polarityte-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-skinte-301546677.html

PRNEWSWIRE
13 May 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty